Paion AG

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for use in out-patient and hospital-based sedation, anesthesia, and critical care services worldwide. The company’s lead product is Remimazolam, an intravenous ultra-short-acting anesthetic, which is in final stage of clinical development for use in procedural sedation, as well as in other indications, such as general anesthesia and intensive care unit sedation. It has partnerships and license agreements with Cosmo Pharmaceuticals, Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm, Pharmascience (Pendopharm), and Mundipharma. Paion AG was founded in 2000 and is headquartered in Aachen, Germany.